Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Vomiting 13Nausea 11Neoplasms 3Leukemia, Myeloid, Acute 2Carcinoma, Non-Small-Cell Lung 2Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Radiation Injuries 1Pruritus 1Postoperative Nausea and Vomiting 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1ITCH 1Hematologic Diseases 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 14fludarabine 12fludarabine phosphate 8Melphalan 8Brentuximab Vedotin 8Whole-Body Irradiation 7Mycophenolic Acid 7Busulfan 7Rituximab 6Tacrolimus 5Lenalidomide 4Etoposide 4isatuximab 3Sirolimus 3Mesna 3Granulocyte Colony-Stimulating Factor 3Dexamethasone 3pembrolizumab 2nilotinib 2dacetuzumab 2Vincristine 2Thiotepa 2Sugars 2Stem Cell Transplantation 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Ondansetron 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methotrexate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Hematologic Diseases × Aprepitant × Clear all
NCT00954941 2015-06-25

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 7 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Nausea, Vomiting, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡